NASDAQ:PLXP - PLx Pharma Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$4.88 +0.53 (+12.18 %)
(As of 01/21/2019 04:00 PM ET)
Previous Close$4.35
Today's Range$4.20 - $5.3215
52-Week Range$1.00 - $7.60
Volume110,323 shs
Average Volume113,108 shs
Market Capitalization$42.70 million
P/E Ratio-2.50
Dividend YieldN/A
Beta2.49
PLx Pharma Inc., a late-stage specialty pharmaceutical company, focuses on developing non-steroidal anti-inflammatory drugs (NSAIDs) and other analgesics. The company's lead product candidates are Aspertec 81 mg and 325 mg, which are novel formulations of aspirin that use the PLxGuard delivery system to reduce acute gastrointestinal (GI) side effects while providing antiplatelet effectiveness for cardiovascular disease prevention. Its product pipeline also includes other oral NSAIDs using the PLxGuard delivery system, including PL1200 Ibuprofen 200 mg, a clinical-stage GI-safer ibuprofen product for pain and inflammation. The company was founded in 2002 and is headquartered in Houston, Texas.

Receive PLXP News and Ratings via Email

Sign-up to receive the latest news and ratings for PLXP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PLXP
CUSIPN/A
Phone713-842-1249

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$780,000.00
Book Value$0.53 per share

Profitability

Net Income$-15,340,000.00

Miscellaneous

Employees14
Market Cap$42.70 million
OptionableNot Optionable

PLx Pharma (NASDAQ:PLXP) Frequently Asked Questions

What is PLx Pharma's stock symbol?

PLx Pharma trades on the NASDAQ under the ticker symbol "PLXP."

How were PLx Pharma's earnings last quarter?

PLx Pharma Inc (NASDAQ:PLXP) announced its earnings results on Friday, November, 9th. The biotechnology company reported ($0.39) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.39). The biotechnology company had revenue of $0.22 million for the quarter. PLx Pharma had a negative net margin of 12.09% and a negative return on equity of 224.24%. View PLx Pharma's Earnings History.

When is PLx Pharma's next earnings date?

PLx Pharma is scheduled to release their next quarterly earnings announcement on Friday, March 22nd 2019. View Earnings Estimates for PLx Pharma.

What price target have analysts set for PLXP?

2 analysts have issued 1-year target prices for PLx Pharma's shares. Their predictions range from $14.00 to $14.00. On average, they expect PLx Pharma's share price to reach $14.00 in the next year. This suggests a possible upside of 186.9% from the stock's current price. View Analyst Price Targets for PLx Pharma.

What is the consensus analysts' recommendation for PLx Pharma?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PLx Pharma in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for PLx Pharma.

Has PLx Pharma been receiving favorable news coverage?

Media headlines about PLXP stock have been trending very positive recently, InfoTrie Sentiment Analysis reports. InfoTrie rates the sentiment of news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. PLx Pharma earned a media sentiment score of 3.2 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 4.0 out of 10, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next few days.

Who are some of PLx Pharma's key competitors?

Who are PLx Pharma's key executives?

PLx Pharma's management team includes the folowing people:
  • Mr. Michael J. Valentino, Exec. Chairman (Age 64)
  • Ms. Natasha Giordano, Chief Exec. Officer, Pres and Director (Age 58)
  • Mr. Gary L. Mossman, Sr. Advisor (Age 77)
  • Mr. Ronald R. Zimmerman, Founder and Sr. Advisor (Age 65)
  • Ms. Rita M. O'Connor, Chief Financial Officer (Age 50)

When did PLx Pharma IPO?

(PLXP) raised $68 million in an IPO on Thursday, February 4th 2016. The company issued 3,800,000 shares at a price of $17.00-$19.00 per share. Raymond James acted as the underwriter for the IPO and Maxim Group LLC and Janney Montgomery Scott were co-managers.

How do I buy shares of PLx Pharma?

Shares of PLXP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is PLx Pharma's stock price today?

One share of PLXP stock can currently be purchased for approximately $4.88.

How big of a company is PLx Pharma?

PLx Pharma has a market capitalization of $42.70 million and generates $780,000.00 in revenue each year. The biotechnology company earns $-15,340,000.00 in net income (profit) each year or ($1.95) on an earnings per share basis. PLx Pharma employs 14 workers across the globe.

What is PLx Pharma's official website?

The official website for PLx Pharma is http://www.plxpharma.com.

How can I contact PLx Pharma?

PLx Pharma's mailing address is 8285 EL RIO STREET SUITE 130, HOUSTON TX, 77054. The biotechnology company can be reached via phone at 713-842-1249 or via email at [email protected]


MarketBeat Community Rating for PLx Pharma (NASDAQ PLXP)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  110 (Vote Outperform)
Underperform Votes:  148 (Vote Underperform)
Total Votes:  258
MarketBeat's community ratings are surveys of what our community members think about PLx Pharma and other stocks. Vote "Outperform" if you believe PLXP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PLXP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/21/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel